- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Merkel cell carcinoma (MCC)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 939.0KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 335.8KB)
Retifanlimab – November 2025
Retifanlimab: Solution concentrate for I.V. infusion 500 mg in 20 mL; Zynyz® - November 2025
Last updated
5 November 2025